In summary, C3G, DP, PCA, AEBS, and Cy effectively alleviate inflammatory responses and pathological progression in RA by inhibiting the activation of the NF-κB, MAPK, and JAK signaling pathways and reducing the release of inflammatory factors, demonstrating their great potential as therapeutic strategies. Here, NFKB1 is linked to rheumatoid arthritis.